These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6985831)

  • 1. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.
    Nissen NI; Pajak TF; Leone LA; Bloomfield CD; Kennedy BJ; Ellison RR; Silver RT; Weiss RB; Cuttner J; Falkson G; Kung F; Bergevin PR; Holland JF
    Cancer; 1980 Jan; 45(2):232-5. PubMed ID: 6985831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.
    Rivera G; Avery T; Pratt C
    Cancer Chemother Rep; 1975; 59(4):743-9. PubMed ID: 1100225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent.
    Sinkule JA
    Pharmacotherapy; 1984; 4(2):61-73. PubMed ID: 6326063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.
    Felix W; Senn HJ
    Cancer Chemother Rep; 1975; 59(4):737-42. PubMed ID: 1100224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer.
    Rubin J; Decker DA; Ahmann DL; Eagan RT; Ingle JN; Hahn RG
    Oncology; 1980; 37(3):149-51. PubMed ID: 7360486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VP-16-213. A phase II trial using a weekly schedule.
    Karp G; Antman K; Canellos G
    Cancer Clin Trials; 1981; 4(4):465-7. PubMed ID: 7318129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration].
    Wakui A; Yokoyama M; Takahashi H; Yoshida Y; Sakata Y; Sato S; Kano A; Kawamoto K; Hashimoto S; Konno K
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):319-29. PubMed ID: 3947109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
    Schiavetti A; Varrasso G; Maurizi P; Cappelli C; Clerico A; Properzi E; Castello MA
    J Pediatr Hematol Oncol; 2000; 22(2):119-24. PubMed ID: 10779024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
    Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
    J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

  • 11. VP 16-213 (VP 16) and cyclophosphamide in the treatment of primitive lung cancer in phase M 1.
    Estape J; Milla A; Agusti A; Lloret JS; Palacin A; Soriano E
    Cancer; 1979 Jan; 43(1):72-7. PubMed ID: 761177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.
    Chard RL; Krivit W; Bleyer WA; Hammond D
    Cancer Treat Rep; 1979; 63(11-12):1755-9. PubMed ID: 294306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.
    Nissen NI; Hansen HH; Pedersen H; Stroyer I; Dombernowsky P; Hessellund M
    Cancer Chemother Rep; 1975; 59(5):1027-9. PubMed ID: 1106845
    [No Abstract]   [Full Text] [Related]  

  • 14. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
    Cavalli F; Sonntag RW; Jungi F; Senn HJ; Brunner KW
    Cancer Treat Rep; 1978 Mar; 62(3):473-5. PubMed ID: 348319
    [No Abstract]   [Full Text] [Related]  

  • 15. VP-16-213 in the treatment of stage III and IV diffuse large cell lymphoma.
    Jacobs P; King HS; Dent DM; Hayes M
    Cancer; 1985 Sep; 56(5):1006-13. PubMed ID: 3893681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.
    Gutierrez ML; Crooke ST
    Cancer Treat Rev; 1979 Sep; 6(3):153-64. PubMed ID: 394834
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study.
    Bennett JM; Lymann GH; Cassileth PA; Glick JH; Oken MM
    Am J Clin Oncol; 1984 Oct; 7(5):471-3. PubMed ID: 6594926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association.
    Jackson DV; Zekan PJ; Caldwell RD; Slatkoff ML; Harding RW; Case LD; Hopkins JO; Muss HB; Richards F; White DR
    J Clin Oncol; 1984 Dec; 2(12):1343-51. PubMed ID: 6096517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
    Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.
    Sierocki JS; Hilaris BS; Hopfan S; Martini N; Barton D; Golbey RB; Wittes RE
    Cancer Treat Rep; 1979; 63(9-10):1593-7. PubMed ID: 227598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.